

Sector: Capital Goods

Result Update

	Change
Reco: Hold	↔
CMP: Rs. 751	
Price Target: Rs. 815	↑

↑ Upgrade ↔ No change ↓ Downgrade


Company details

Market cap:	Rs. 8,950 cr
52-week high/low:	Rs. 1180/644
NSE volume: (No of shares)	1 lakh
BSE code:	500411
NSE code:	THERMAX
Sharekhan code:	THERMAX
Free float: (No of shares)	4.5 cr

Shareholding (%)

Promoters	62.0
FII	7.8
DII	17.6
Others	12.7

Price chart



Price performance

(%)	1m	3m	6m	12m
Absolute	6	5	-29	-29
Relative to Sensex	-6	-12	-12	-16

Sharekhan Research, Bloomberg

Thermax's consolidated net revenue reported a sharp decline of 36.2% y-o-y in revenue for Q4FY2020 (lower than our estimates) at Rs. 1,323 crore due to impact of lockdown (loss of revenue of Rs. 400 crore-500 crore), wherein the decline in revenue was seen across segments. Operating profit margin (OPM) declined by 343 bps y-o-y, led by lower absorption of fixed costs on lower revenue. Hence, operating profit fell sharply by 63% y-o-y to Rs. 64 crore. Further, lower other income (-41% y-o-y to Rs. 30.7 crore) and higher depreciation (+25% y-o-y to Rs. 30.8 crore) impacted PBT (-70% y-o-y) and adjusted PAT declined by 70% y-o-y to Rs. 39 crore (sharply lower than our estimate). Order inflow declined by 17.7% y-o-y with FY2020 order intake at Rs. 5,498 crore (-2.4% y-o-y). Accordingly, order backlog dropped by 2.5% y-o-y to Rs. 5,238 crore (-4% q-o-q; 0.9x its FY2020 revenue). Weak international order inflows and limited visibility for big-ticket size domestic orders largely (in steel, cement, and fertilisers) led to management guiding for lower order inflows in FY2021 compared to FY2020, given the current uncertainties. However, management expects better ordering in its chemical business; and enquiries pipeline remains positive in food processing, FMCG, oil and gas refinery, and pharma in domestic markets. Management stated that all factories have started operating, which is currently at 40-45% utilisation levels and expect to return to normalcy by Q3FY2021. Further, 90-95% of the project sites are operating at 50-60% of labour, so execution will not be a challenge at present; and management expects more labour to come gradually as things improve. The fire at the adjoining facility of Dahej chemical factory affected its factory, which would lead to 30-40 days of production loss impacting the chemical division's revenue. We have tweaked our estimates for FY2021-FY2022, factoring lower order booking and challenges pertaining to the uncertainties related to execution and production. We retain our Hold rating with a revised price target (PT) of Rs. 815.

Key positives

- ♦ Strong improvement in operating cash flows during FY2020 as against FY2019.
- ♦ Better ordering expected in the chemical segment, while enquiries pipeline remains positive in food processing, FMCG, and pharma in domestic markets.

Key negatives

- ♦ Order booking declined by 17% y-o-y.
- ♦ Management has guided for lower order booking for FY2021 compared to FY2020.

Our Call

Valuation – Maintain Hold with a revised PT of Rs. 815: Lower carry-forward order book along with lower capacity utilisation in most core user industries is likely to impact order inflows for FY2021. Additionally, weak order intake outlook during FY2021 may lead to further depletion of order book by the end of FY2021. Hence, order inflow during the current fiscal year would be the key monitorable for the company. Further, H1FY2020 is expected to be remain weak owing to COVID-19 pandemic and damage caused at its Dahej facility. The company is expected to return to normalcy by Q3FY2021. On the positive note, the company has been able to improve its cash flow position during FY2020. We have tweaked our estimates for FY2021-FY2022, factoring lower order booking and challenges pertaining to uncertainties related to execution and production. We retain our Hold rating with a revised PT of Rs. 815.

Key Risks

Slower-than-expected revival in private capex resulting in muted order picking.

Valuation (Consolidated)

	Rs cr			
Particulars	FY19	FY20	FY21E	FY22E
Revenue	5,973	5,731	5,168	5,856
OPM (%)	7.7	7.1	7.0	8.5
Adjusted PAT	325	212	250	353
% YoY growth	40.8	(34.7)	17.8	41.2
Adjusted EPS (Rs.)	28.9	18.9	22.2	31.4
P/E (x)	26.0	39.8	33.8	24.0
P/B (x)	2.8	2.8	3.2	2.8
EV/EBITDA (x)	12.3	14.5	15.8	11.1
RoNW (%)	14.6	7.1	8.9	12.9
RoCE (%)	18.7	13.2	11.6	16.6

Source: Company; Sharekhan estimates

Weak performance for the quarter: Thermax's consolidated net revenue reported a sharp decline of 36.2% y-o-y during Q4FY2020 (lower than estimates) at Rs. 1,323 crore due to impact of lockdown (Rs. 400 crore-500 crore impact), wherein the revenue decline was seen across segments. Operating profit margin (OPM) declined by 343 bps y-o-y due to higher other expenses (one-time warranty provisioning, bad debts written down, higher freight and site expenses) and lower revenue. Hence, operating profit fell sharply by 63% y-o-y to Rs. 64 crore. Further, lower other income (-41% y-o-y to Rs. 30.7 crore) and higher depreciation (+25% y-o-y to Rs. 30.8 crore) impacted PBT growth (-70% y-o-y) and adjusted PAT declined by 70% y-o-y to Rs. 39 crore (sharply lower than our estimates) due to lower revenue and margins.

Declining order book remains a concern: Order inflow declined by 17.7% y-o-y, with FY2020 order intake at Rs. 5,498 crore (-2.4% y-o-y). Accordingly, order backlog dropped by 2.5% y-o-y to Rs. 5,238 crore (-2.5% y-o-y and -4% q-o-q; 0.9x FY2020 revenue). Weak international order inflows and limited visibility for big-ticket size domestic orders largely (in steel, cement and fertilisers) led to management guiding for lower order inflows in FY2021 compared to FY2020, given the current uncertainties. Management expects better ordering in its chemical business; and enquiries pipeline remains there in food processing, FMCG, oil and gas refinery, and pharma in domestic markets. The company expects better exports from the chemical division due to opportunities arising from pharma API factories (for boilers, water treatment etc.) and orders from international markets (North America).

Key conference call highlights

- ♦ **Order inflow guidance:** Weak international order inflows and limited visibility for big-ticket size domestic orders largely (in steel, cement and fertilisers) led to management guiding for lower order inflows in FY2021 compared to FY2020, given the current uncertainties.
- ♦ **Procurement from China:** Management highlighted that procurement from China compared to overall procurement from other countries remains miniscule (currently at Rs. 154 crore).
- ♦ **Domestic market order intake scenario:** In the domestic market, the company expects better ordering in its chemical business; and enquiries pipeline remains positive in food processing, FMCG, and pharma in domestic markets.
- ♦ **FGD Orders:** The company has bid for some flue-gas desulfurization (FGD) orders in Lot-5 and would be bidding for more orders in LOT-6 of FGD bidding. Thermax seems less interested for bidding for State Electricity Boards (SEB) FGD orders due to cash crunch in most SEBs.
- ♦ **Current factory status after lockdown:** Management stated that all factories have started operating, which is currently at 40-45% utilisation levels, and expects to return to normalcy by Q3FY2021. Further, project sites are operating at 90-95% levels and have retained 50-60% of labour so execution will not be a challenge at present and management expects more labour to come gradually as things improve.
- ♦ **International business update:** The company's factories in Denmark, Germany, Poland, and Indonesia were operational. Further, Danstoker continues to be loss making and is expected to be closer to breakeven by FY2021 end. Further, Indonesia plant is loss making at present but losses are coming down.
- ♦ **Impact from Coronavirus outbreak:** Due to COVID-19 led lockdown, the company was unable to dispatch products and raw materials, which led to lower revenue recognition (impact of Rs. 400 crore-500 crore) during Q4FY2020.
- ♦ **Fire at Dahej factory some time back:** Management highlighted that there was fire in its Dahej chemical factory sometime back (earlier reported) and it lost 30-40 days of production, which impacted revenue. However, the company expects better exports from the chemical division due to opportunities arising from pharma API factories (for boilers, water treatment etc.) and orders from international markets (North America).

Results (Consolidated)

Particulars	Q4FY20	Q4FY19	YoY %	Q3FY20	Rs cr QoQ %
Net sales	1,323.0	2,074	-36.2%	1,410	-6%
Net raw material	673	1,255	-46.4%	785	-14%
Employee Expenses	197	205	-3.8%	200	-1%
Other Expenses	389	443	-12.1%	312	25%
Operating profit	63.6	171	-62.8%	113	-44%
Other Income	31	52	-40.9%	26	19%
Interest	4.9	3.5	39.6%	1.9	154%
Depreciation	31	25	24.8%	32	-3%
PBT	59	195	-69.9%	105	-44%
Tax	20	65	-70.0%	20	-4%
Adj. PAT	39.0	128.9	-69.7%	85	-54%
Rep. PAT	39	127	-69.2%	85	-54%
EPS (Rs.)	3.5	11.3	-69.2%	7.5	-54%
Margin			bps		bps
OPM	4.8%	8.2%	(343)	8.0%	(322)
PATM	3.0%	6.2%	(327)	6.0%	(308)
Tax rate	33.4%	33.6%		19.4%	

Source: Company, Sharekhan Research


Outlook

Cautious on near-term recovery in order tendering: Management sounded cautious on a short-term recovery in order tendering. Weak international order inflows and limited visibility for big ticket-size domestic led to management guiding for lower order inflows in FY2021 compared to FY2020. Management also expects more FGD orders for tendering in domestic markets and would be bidding accordingly. Management expects better ordering in its chemical business. Further enquiries pipeline remains positive in food processing, FMCG, oil and gas refinery, and pharma in domestic markets. The company expects better exports from the chemical division due to opportunities arising from pharma API factories (for boilers, water treatment etc.) and orders from international markets (North America).

Valuation

Maintain Hold with a revised PT of Rs. 815: Lower carry-forward order book along with lower capacity utilisation in most core user industries is likely to impact order inflows for FY2021. Additionally, weak order intake outlook during FY2021 may lead to further depletion of order book by the end of FY2021. Hence, order inflows during the current fiscal year would be the key monitorable for the company. Further, H1FY2020 is expected to remain weak owing to COVID-19 pandemic and damage caused at its Dahej facility. The company is expected to return to normalcy by Q3FY2021. On the positive note, the company has been able to improve its cash flow position during FY2020. We have tweaked our estimates for FY2021-FY2022, factoring lower order booking and challenges pertaining to uncertainties related to execution and production. We retain our Hold rating with a revised PT of Rs. 815.

One-year forward P/E (x) band



Source: Sharekhan Research

About company

Thermax provides solutions in the energy and environment space. The energy business contributes 75-78% to revenue, whereas the environment business contributes 15-16% and chemical business contributes 7-8%. The company operates globally through 33 international offices and 13 manufacturing facilities, seven of which are in India and six are overseas. Thermax is present in 86 countries across Asia Pacific, Africa, Middle East, CIS countries, Europe, US, and South America.

Investment theme

Green shoots of a revival in private capex are visible in a few segments (metals and cement), with most other companies resorting to brownfield expansions. However, a broad-based recovery is key for Thermax. While historically, Thermax's growth has been led by the domestic market, incremental growth from international markets exposes Thermax to the risk of rising commodity prices, given fixed-price contracts.

Key Risks

- ♦ Slower-than-expected revival in private capex resulting in muted order picking
- ♦ Slowdown in tendering activities, and slower pick-up in its subsidiary companies.

Additional Data

Key management personnel

Meher Pudumjee	Chairman
Nawshir Mirza	Additional Independent Director
M S Unnikrishnan	Managing Director
Pheroz Pudumjee	Non Executive Promoter
Anu Aga	Non Executive Promoter

Source: Company Website

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	RDA Holdings Pvt Ltd	53.99
2	ARA TRUSTEESHIP COMPANY PVT LTD	7.99
3	SBI Funds Management Pvt Ltd	3.36
4	PineBridge Investments LP	3.17
5	Kotak Mahindra Asset Management Co	2.27
6	Goldman Sachs Group Inc/The	1.64
7	Franklin Resources Inc	1.63
8	L&T Mutual Fund Trustee Ltd/India	1.53
9	Life Insurance Corp of India	1.48
10	Reliance Capital Trustee Co Ltd	1.22

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Sharekhan

by BNP PARIBAS

Know more about our products and services

For Private Circulation only

Disclaimer: This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he or its associates or his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: compliance@sharekhan.com;

For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com

Registered Office: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVL R, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.